In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 8, 2001, Pages 2372-2374

  Betriu, C ^a   Sanchez A ^a   Palau, M L ^a   Gomez M ^a   Picazo, J J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFMINOX; CEFOTETAN; CEFOXITIN; CEFTIZOXIME; CHLORAMPHENICOL; CLINDAMYCIN; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; TROVAFLOXACIN;

ANAEROBIC INFECTION; ARTICLE; BACTEROIDES FRAGILIS; CONTROLLED STUDY; DRUG ACTIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTEROIDES FRAGILIS; CARBAPENEMS; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0034927829     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.8.2372-2374.2001     Document Type: Article

References (14)

1. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamicins, penicillins, clindamycin, and metronidazole in the United States
2. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species
3. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: A 4-year study
4. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents
5. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: Comparison with the activities of 14 other agents
6. In vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests
7. Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections
8. Comparative in vitro activities of carbapenem, L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens
9. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates
10. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada
11. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996
12. Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers
13. In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria